Health Canada to start real-time review of Pfizer-BioNTech COVID-19 vaccine
(Reuters) - Health Canada will launch a real-time review of Germany’s BioNTech SE and Pfizer Inc.’s experimental COVID-19 vaccine on Friday.
The companies said they would provide the Canadian Department of Health with safety and efficacy data from their COVID-19 vaccine trial as an ongoing filing when it becomes available.
Continuous review allows researchers to submit results in real time without waiting for studies to complete. Canadian Health Minister Patty Hajdu signed an ordinance last month that allows companies developing COVID-19 vaccines to submit information as soon as it becomes available.
Health Canada said it would not make a decision on whether to approve a vaccine that is undergoing ongoing review until it has received the necessary evidence to demonstrate the candidate's safety, effectiveness and quality.
The EU health authority on Tuesday launched a real-time review of the companies' experimental COVID-19 vaccine, potentially speeding up the process of getting a vaccine approved.
The Canadian Department of Health began a real-time review of the vaccine candidate from AstraZeneca and Oxford University a week ago to expedite the potential approval of a COVID-19 vaccine. (https://reut.rs/2If5GWM)
(Reporting by Trisha Roy in Bengaluru; editing by Shinjini Ganguli)
You should check here to buy the best price guaranteed products.
Rep. Madison Cawthorn's Question About 'The Biggest Lie' Backfires Spectacularly
Kristen Stewart wore a daring crop top and a sheer skirt to the 'Spencer' premiere
Ambidextrous artist wows TikTok with his unique skill
Saudi Arabia told international companies to move their regional headquarters to its capital or lose out on government contracts. It's working.
D'Angelo Russell with a deep 3 vs the Milwaukee Bucks
Futures Rise as Tesla Keeps Accelerating